Compassionate-Use Antifungals: What Clinicians Can Almost Access Now

Originally published by our sister publication Infectious Disease Special EditionBy Gina ShawDespite decades of need, antifungal drug development has produced relatively few mechanistically novel agents. Clinicians treating invasive fungal infections continue to rely on three primary classes—azoles, echinocandins, and polyenes—targeting just two major pathways.“We’re actually pretty good at making antifungals. What we struggle with is making good antifungals that are not